Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1144 | Thyroid cancer | ECE2018

Changing treatment trends with radioiodine in thyroid carcinoma at the beginning of 21st century in Castilla-La Mancha (Spain)

Delgado Manuel , Sastre Julia , Quiroga Ivan , Gonzalez Javier , Torres Belvis , Aznar Silvia , Alvarez Visitacion , Herranz Sandra , Moreno Jesus , Gomez Paz

Background and objective: The incidence of differentiated thyroid carcinoma (DTC) is increasing worldwide. Radioiodine (RAI) ablation is one of the main elements in the therapy of DTC after surgical removal of the gland. This study aims to compare the use of I131 in a Spanish Cohort of DTC before and after the American Thyroid Association (ATA) 2009 guidelines.Patients and methods: The Cadit-CAM study was designed to evaluate retrospectively characterist...

ea0092ps2-12-06 | Nodules 1 | ETA2023

Assessment of an artificial intelligence-based decision support system in the thyroid nodule evaluation in clinical practice

Fernandez-Velasco Pablo , Torres Beatriz , Delgado Esther , Perez-Lopez Paloma , Benito-Sendin Plaar Katia , de Luis Daniel , Diaz-Soto Gonzalo

Objective: To evaluate the impact of a decision support system (DSS) based on artificial intelligence (AI) -KoiosDS- on ultrasound (US) image analysis and risk stratification in thyroid nodules.Material and methods: Retrospective US study of all thyroid nodules with histologic (AP) result from June 2020 to December 2021. Diagnostic performance of US with ACR-TIRADS, by six endocrinologists and DSS, before and after the use of AI was evaluated.<p clas...

ea0099ep865 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Impact of the use of continuous subcutaneous insulin infusion versus multiple daily insulin injections in adults with type 1 diabetes mellitus

Zayas Aguilar Irene , Jesus Lucena Morales Cristian , Lara Barea Almudena , de los Angeles Cutilla Munoz Maria , Maria Torres Barea Isabel

Objective: The aim of this study is to assess the impact of continuous subcutaneous insulin infusion (CSII) via a pump for patients with type 1 diabetes mellitus (DM1) on blood glucose and metabolic control.Materials and methods: A descriptive study was performed in a cohort of patients with DM1, showing blood glucose measurements at one month, six months and one year after implantation of the CSII. In addition, we performed an intra-subject before-after...

ea0099ep987 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Glucometric comparison in DM1 patients after implantation of continuous glucose monitoring

Martinez Silla Elena , Redondo Torres Enrique , Garcia Sanchez Javier , Rodriguez Juarez Raul , Quesada Charneco Miguel , Lopez-Ibarra Lozano Pablo-Jose

Introduction and Objectives: Continuous glucose monitoring (CGM) has demonstrated benefits in the prevention of hypoglycemia in patients with type 1 diabetes mellitus (DM1) vs flash monitoring (CGM). Our aim was to analyze the clinical characteristics, indication and glucometric changes in patients using MFG after CGM implantation.Material and methods: Retrospective observational study of 13 patients under follow-up for DM1 in Endocrinology consultations...

ea0099ep158 | Endocrine-Related Cancer | ECE2024

A new kind of hypophysitis: adverse effect of ICPIs

Torres Arroyo Belvis , Martinez Ana , Suarez Carolina , Maldonado Gonzalo , Gomez Jose , Angel Valero Miguel , Quiroga Ivan , Blanco Benito

Introduction: Hypophysitis is a rare disease. Lately, it is more frequent due to the use of Inmune Check Point Inhibitor (ICPIs). Ipilimumab or combo Ipilimumab + Nivolumab are the main cause. Agree with literature, 17-18% of the patients with these drugs suffer from. By contrast, with Idiopatic Autoimmune Hypophysitis and Lymphocytic Hypophysitis, this type of hypophysitis occurs in sixties men. Autoinmunity mechanism is known, but precise pathophysiology is unclear <p cl...

ea0099ep549 | Reproductive and Developmental Endocrinology | ECE2024

Premature ovarian failure after cancer treatment: surveillance and management

Lopes-Pinto Mariana , Calheiros Raquel , Santos Sara , Inacio Isabel , Souteiro Pedro , Oliveira Joana , P Santos Ana , Torres Isabel

Introduction: Cancer treatment including oophorectomy, radiotherapy and chemotherapy with gonadotoxic agents may induce premature ovarian failure. Early diagnosis and treatment of ovarian failure avoids cardiovascular disorders, osteoporosis and compromised sexual health due to estrogen deficiency and also ensures growth and pubertal development in children.Aim: Raise awareness for early assessment and management of premature ovarian failure after cancer...

ea0081p535 | Adrenal and Cardiovascular Endocrinology | ECE2022

Minimally invasive treatment of conn’s adenoma: real world cases in tertiary oncology center

Costa Claudia , Franco Sara , Santos Ana Paula , Goncalves Belarmino , Gil-Santos Sara , Oliveira Joana , Souteiro Pedro , Jose Sousa Maria , Torres Isabel

Introduction: Primary aldosteronism (PA) is a rare but underestimated cause of hypertension. PA has been associated with increased risk of malignancy through mechanisms involving up-regulation of the renin angiotensin system (RAS) promoting an enzymatic cascade influencing carcinogenesis. Recently, Microwave Ablation (MWA) has been established as an effective and safe minimal invasive treatment for Conn’s Disease.Aim: The authors present four clinic...

ea0090p388 | Endocrine-related Cancer | ECE2023

PRRT 177Lu-DOTA-TATE in pancreatic neuroendocrine tumors – When to initiate?

Franco Sara , Lucena Sampaio Ines , Ferreira Goncalo , Barbosa Daniel , Gil-Santos Sara , Vara Luiz Henrique , Paula Santos Ana , Torres Isabel , Duarte Hugo

Introduction: The best timing for PRRT (peptide receptor radionuclide therapy) in the case of pancreatic neuroendocrine tumors (panNETs) is still to define, as randomized prospective trials are lacking. Recent studies suggest that some systemic therapies can affect response to PRRT, favoring an earlier use of the latter.Objective: To determine the efficacy and toxicity of PRRT, comparing its results when used as a second line systemic therapy (a...

ea0090ep596 | Endocrine-related Cancer | ECE2023

Case Report: Successful treatment of an atypical lung neuroendocrine neoplasm with PRRT

Guerreiro Vanessa , Lucena Ines , Paula Santos Ana , Prospero Ines , Ferreira Goncalo , Gil Santos Sara , Oliveira Joana , Freitas Paula , Torres Isabel , Duarte Hugo

Neuroendocrine neoplasms (NENs) arise from specialized cells called neuroendocrine cells spread through the body, mainly in the gastrointestinal tract, pancreas and lung. Pathological classification of Lung NENs include well differentiated NENs, that can be classified as typical or atypical carcinoids, and poorly differentiated neuroendocrine carcinomas (NECs), classified as small-cell lung carcinoma (SC-NEC) or large-cell neuroendocrine carcinoma (LC-NEC). We present a case o...

ea0090ep599 | Endocrine-related Cancer | ECE2023

Treatment with 177Lu-dotatate in metastasic advanced neuroendocrine tumors with positive expression of somatostatin receptors, in a third level hospital in Spain from 2015–2022

Giron Giselle , Hernandez Lorena , ISABEL DEL OLMO GARCIA MARIA , Camara-Gomez Rosa , Bello Pilar , Prado Stephan , Segura Angel , Francisco Merino Torres Juan

Introduction: 177Lu-Oxodotreotide(PRRT-Lu) has the approval by EMA and FDA since 2017 for the treatment of patients with gastro-entero-pancreatic neuroendocrine tumors(GEP-NET). However, in daily clinical practice it has also been used in other NET tumors such as paragangliomas, lung NET, medullary thyroid cancer, and others. The aim of this study is to describe the characteristics and follow-up of patients treated with PRRT-Lu in a third level hospital in Spain fro...